Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

Inclusion Criteria: * Age between 40 and 65. * Both genders will be included. * Type II diabetes mellitus confirmed by Glycosylated Hemoglobin A₁C. * Diagnosis of diabetic nephropathy, which will be defined as persistent albuminuria with urinary albumin creatinine ratio (UACR) range \[30-300 mg /gm\], confirmed on at least two occasions 3-6 months apart, with or without decline in glomerular filtration rate at screening and receiving angiotensin receptor blockers (ARBs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors therapy. * Hemoglobin A₁C ranges from 6.5% to 10% with regular use of insulin and or/oral hypoglycemic drugs. Exclusion Criteria: * Other types of diabetes mellitus * Uncontrolled hypertension (Blood pressure ≥ 180/110). * Urinary tract infection. * Severe anemia (Hemoglobin ˂10). * Critically ill patient. * Past operation, past history of trauma, heavy exercise. * Severe renal failure (e GFR ˂ 30ml/min/1.73 m2). * Systemic inflammatory and autoimmune diseases. * Malignancy. * Pregnancy and lactating women. * Other causes of chronic kidney disease.